Predicting substrates of the human breast cancer resistance protein using a support vector machine method
暂无分享,去创建一个
Zsolt Bikádi | Eszter Hazai | Istvan Hazai | Isabelle Ragueneau-Majlessi | Sophie P. Chung | Qingcheng Mao | E. Hazai | Qingcheng Mao | Z. Bikádi | I. Ragueneau-Majlessi | I. Hazai
[1] M. D. Boer,et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein , 2004, Leukemia.
[2] A. V. van Herwaarden,et al. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. , 2006, Carcinogenesis.
[3] Y. Sugimoto,et al. Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.
[4] Jos H Beijnen,et al. P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib Metabolite N-Desethyl Sunitinib , 2012, Journal of Pharmacology and Experimental Therapeutics.
[5] Stephan Kopp,et al. Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.
[6] Y. Sugimoto,et al. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants , 2003, International journal of cancer.
[7] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[8] F H Hausheer,et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Yuichi Sugiyama,et al. Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2) , 2005, Pharmaceutical Research.
[10] Gary Williamson,et al. Predicting Phenolic Acid Absorption in Caco-2 Cells: A Theoretical Permeability Model and Mechanistic Study , 2012, Drug Metabolism and Disposition.
[11] D. Voelker,et al. Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2* , 2010, The Journal of Biological Chemistry.
[12] Hikaru Saito,et al. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. , 2006, Cancer letters.
[13] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[14] Honggang Wang,et al. The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study , 2007, Molecular Pharmacology.
[15] Baojian Wu,et al. UDP-Glucuronosyltransferase (UGT) 1A9-Overexpressing HeLa Cells Is an Appropriate Tool to Delineate the Kinetic Interplay between Breast Cancer Resistance Protein (BRCP) and UGT and to Rapidly Identify the Glucuronide Substrates of BCRP , 2012, Drug Metabolism and Disposition.
[16] A. Schinkel,et al. TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) , 2005, Drug Metabolism and Disposition.
[17] Yi Zhang,et al. HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[18] T Ishikawa,et al. Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2. , 2012, Mini reviews in medicinal chemistry.
[19] Li Li,et al. pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein , 2011, Drug Metabolism and Disposition.
[20] Nicolas Tournier,et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). , 2010, The international journal of neuropsychopharmacology.
[21] Nicolas Tournier,et al. Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening , 2011, The Journal of Nuclear Medicine.
[22] Giancarlo Albo,et al. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins. , 2008, European journal of pharmacology.
[23] B. Torok-Storb,et al. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.
[24] P. Carrupt,et al. QSAR analysis and molecular modeling of ABCG2-specific inhibitors. , 2009, Advanced drug delivery reviews.
[25] Jos H. Beijnen,et al. Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.
[26] Francesca Borrelli,et al. Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. , 2007, Journal of medicinal chemistry.
[27] Yuichi Sugiyama,et al. Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one) , 2007, Drug Metabolism and Disposition.
[28] Yves Pommier,et al. ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins , 2004, Journal of Pharmacology and Experimental Therapeutics.
[29] G. Merino,et al. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. , 2006, Journal of veterinary pharmacology and therapeutics.
[30] S. Balleydier,et al. Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters. , 2007, Toxicology letters.
[31] Jos H. Beijnen,et al. Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.
[32] F. Meng,et al. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity , 2008, Cancer Chemotherapy and Pharmacology.
[33] S. Bates,et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. , 2003, Cancer research.
[34] H. Rosing,et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] Yong-Hae Han,et al. Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells , 2008, Pharmaceutical Research.
[36] J. Espín,et al. Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice , 2011, Drug Metabolism and Disposition.
[37] Yehuda G. Assaraf,et al. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates , 2006, Cancer Chemotherapy and Pharmacology.
[38] R. Rosales,et al. Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta , 2012, Molecular Pharmacology.
[39] Jeffrey C Stevens,et al. Preclinical and Clinical Evidence for the Collaborative Transport and Renal Secretion of an Oxazolidinone Antibiotic by Organic Anion Transporter 3 (OAT3/SLC22A8) and Multidrug and Toxin Extrusion Protein 1 (MATE1/SLC47A1) , 2010, Journal of Pharmacology and Experimental Therapeutics.
[40] Alfonso Lampen,et al. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. , 2005, Carcinogenesis.
[41] Jos H. Beijnen,et al. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2 , 2007, Molecular Cancer Therapeutics.
[42] Yang Dai,et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan , 2006, Cancer Chemotherapy and Pharmacology.
[43] Suneet Shukla,et al. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2 , 2007, Molecular Cancer Therapeutics.
[44] G. Hankins,et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. , 2010, Biochemical pharmacology.
[45] J. Allen,et al. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. , 2001, Bioorganic & medicinal chemistry letters.
[46] Eszter Hazai,et al. Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein , 2011, PloS one.
[47] T. Litman,et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.
[48] F. Lee,et al. Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2) , 2011, Journal of Pharmacology and Experimental Therapeutics.
[49] Gilbert Bensimon,et al. Interactions between riluzole and ABCG2/BCRP transporter , 2009, Neuroscience Letters.
[50] Yiyu Cheng,et al. Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..
[51] S. Bates,et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.
[52] S. Bates,et al. Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.
[53] Atsushi Ose,et al. Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds , 2008, Drug Metabolism and Disposition.
[54] J. F. Wang,et al. Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach , 2004, J. Chem. Inf. Model..
[55] Mariël Brok,et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.
[56] Kelly H. Jordan,et al. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[57] Massimo Zucchetti,et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences , 2009, Cancer Chemotherapy and Pharmacology.
[58] Yuichi Sugiyama,et al. ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.
[59] Jos H Beijnen,et al. Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.
[60] Yuichi Sugiyama,et al. Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens , 2007, Molecular Pharmacology.
[61] A. Sparreboom,et al. Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism , 2011, Clinical pharmacology and therapeutics.
[62] Yuichi Sugiyama,et al. Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect , 2007, Drug Metabolism and Disposition.
[63] Xin Wang,et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.
[64] Gideon Koren,et al. Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. , 2011, Canadian journal of physiology and pharmacology.
[65] K. Német,et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance , 2008, Annals of the rheumatic diseases.
[66] Suneet Shukla,et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. , 2011, Molecular pharmaceutics.
[67] Marilyn E. Morris,et al. Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.
[68] Xin Wang,et al. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. , 2004, Biochemical pharmacology.
[69] Jos H Beijnen,et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.
[70] H. Kotani,et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. , 2001, Cancer research.
[71] Balázs Sarkadi,et al. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. , 2005, Biochimica et biophysica acta.
[72] M R Baer,et al. Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia , 2008, Leukemia.
[73] Gajendra PS Raghava,et al. RESEARCH ARTICLE Open Access Research article Prediction of cytochrome P450 isoform responsible , 2022 .
[74] H. Rosing,et al. Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.
[75] Piet Borst,et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides , 2008, Molecular Cancer Therapeutics.
[76] S. Nishimura,et al. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. , 2002, Biochemical and biophysical research communications.
[77] P. Pávek,et al. Lack of Interactions between Breast Cancer Resistance Protein (BCRP/ABCG2) and Selected Antiepileptic Agents , 2006, Epilepsia.
[78] D. Ross,et al. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.
[79] Yuichi Sugiyama,et al. Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones , 2007, Drug Metabolism and Disposition.
[80] Marilyn E Morris,et al. The Bioflavonoid Kaempferol Is an Abcg2 Substrate and Inhibits Abcg2-Mediated Quercetin Efflux , 2011, Drug Metabolism and Disposition.
[81] Kazuya Maeda,et al. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor , 2007, Drug Metabolism and Disposition.
[82] S. Vaidhyanathan,et al. Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) , 2012, Journal of Pharmacology and Experimental Therapeutics.
[83] J. Schellens,et al. Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.
[84] Yehuda G Assaraf,et al. Structural Determinants of Imidazoacridinones Facilitating Antitumor Activity Are Crucial for Substrate Recognition by ABCG2 , 2009, Molecular Pharmacology.
[85] Kim L R Brouwer,et al. The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice , 2006, Molecular Pharmacology.
[86] Qingcheng Mao,et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). , 2010, Current drug metabolism.
[87] Pedro Gonçalves,et al. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. , 2011, American journal of physiology. Cell physiology.
[88] Yan Ji,et al. Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). , 2005, Molecular pharmaceutics.
[89] Weiwei Hu,et al. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population , 2010, In Vitro Cellular & Developmental Biology - Animal.
[90] Andreas Bender,et al. P-glycoprotein Substrate Models Using Support Vector Machines Based on a Comprehensive Data set , 2011, J. Chem. Inf. Model..
[91] M. Pomper,et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. , 2007, Cancer research.
[92] Daxi Sun,et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. , 2007, Cancer research.
[93] E. Hudson,et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.
[94] V. Soto-Cerrato,et al. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. , 2004, Biochemical pharmacology.
[95] O. Ogawa,et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[96] Jos H. Beijnen,et al. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models , 2007, Molecular Pharmacology.
[97] Fan Zhang,et al. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. , 2011, Biochemical pharmacology.
[98] Michael Wiese,et al. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.
[99] Michael Dean,et al. The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. , 2006, Research in veterinary science.
[100] S. Rabindran,et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.
[101] Francisco Gamarro,et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.
[102] Jos H Beijnen,et al. Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone , 2009, Drug Metabolism and Disposition.
[103] Alfred H. Schinkel,et al. Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.
[104] Shuzhong Zhang,et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.
[105] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[106] Manuel Hidalgo,et al. In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent , 2005, Clinical Cancer Research.
[107] Yi Zhang,et al. BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers , 2005, Pharmaceutical Research.
[108] Jos H. Beijnen,et al. P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin , 2007, Antimicrobial Agents and Chemotherapy.
[109] E. L. Volk,et al. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.
[110] Robert W. Robey,et al. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells , 2009, Cancer Chemotherapy and Pharmacology.
[111] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[112] Suneet Shukla,et al. Modulation of the function of the multidrug resistance–linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin , 2006, Molecular Cancer Therapeutics.
[113] Yoshihiko Ueda,et al. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. , 2012, Oncology reports.
[114] T. Ishikawa,et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.
[115] Suzanne Skolnik,et al. Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model , 2011, Drug Metabolism and Disposition.
[116] BMC Bioinformatics , 2005 .
[117] Bo Feng,et al. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[118] Jing Li,et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients , 2007, Cancer biology & therapy.
[119] Mark N Milton,et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. , 2010, Drug metabolism letters.
[120] Suneet Shukla,et al. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter , 2007, Molecular Cancer Therapeutics.
[121] Alfred H. Schinkel,et al. BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION , 2006, Drug Metabolism and Disposition.
[122] Yves Pommier,et al. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters , 2007, Molecular Cancer Therapeutics.
[123] Marilyn E Morris,et al. The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). , 2011, Biopharmaceutics & drug disposition.
[124] Takashi Usui,et al. Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein , 2011, Drug Metabolism and Disposition.
[125] Yuichi Sugiyama,et al. Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.
[126] Bo Feng,et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human , 2007, Drug Metabolism and Disposition.
[127] Jos H Beijnen,et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.
[128] C. Paulusma,et al. Oral Availability of Cefadroxil Depends on ABCC3 and ABCC4 , 2012, Drug Metabolism and Disposition.
[129] A. Schinkel,et al. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.
[130] Hui Zhang,et al. A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method , 2011, Comput. Biol. Medicine.
[131] N. Shaik,et al. Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.
[132] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[133] Suneet Shukla,et al. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.
[134] Joe Palandra,et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.
[135] S. Bates,et al. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.
[136] A. V. van Herwaarden,et al. The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.
[137] Teruko Imai,et al. Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. , 2011, Journal of pharmaceutical sciences.
[138] M. J. van de Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[139] A. G. Blazquez,et al. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. , 2009, Chemico-biological interactions.
[140] S H Kaufmann,et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.
[141] R. Ford,et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. , 2010, Structure.
[142] Piet Borst,et al. Intestinal Breast Cancer Resistance Protein (BCRP)/Bcrp1 and Multidrug Resistance Protein 3 (MRP3)/Mrp3 Are Involved in the Pharmacokinetics of Resveratrol , 2009, Molecular Pharmacology.
[143] Takashi Tsuruo,et al. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. , 2003, Molecular pharmacology.
[144] S. Bates,et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.
[145] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[146] Franciska Erdő,et al. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. , 2012, Drug metabolism and pharmacokinetics.
[147] E. Boerwinkle,et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.
[148] Jos H Beijnen,et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.
[149] A. Calcagno,et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor , 2006, Molecular Cancer Therapeutics.
[150] Suneet Shukla,et al. Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen , 2009, Molecular Pharmacology.
[151] Sarah Spiegel,et al. Estradiol Induces Export of Sphingosine 1-Phosphate from Breast Cancer Cells via ABCC1 and ABCG2* , 2010, The Journal of Biological Chemistry.
[152] T. Litman,et al. Functional analysis of candidate ABC transporter proteins for sitosterol transport. , 2002, Biochimica et biophysica acta.
[153] Guoyu Pan,et al. Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine , 2007, Drug Metabolism and Disposition.
[154] Piet Borst,et al. cGMP transport by vesicles from human and mouse erythrocytes , 2007, The FEBS journal.